Genetic polymorphisms of CYP3A5, CHRM2, and ZNF498 and their association with epilepsy susceptibility: a pharmacogenetic and case-control study.

Laith Naser Al-EitanIslam M Al-DalalahMohamed M Mustafa Mansour Abdullah AlghamdiAfrah K ElshammariWael H Khreisat Mohammed N Al-Quasmi Hanan A Aljamal

Published in: Pharmacogenomics and personalized medicine (2019)

Our results failed to confirm the association of CYP3A5, ZNF498, and CHRM2 variants with either disease development or treatment response. Clinical pharmacogenetic studies may contribute to treatment personalization, appropriate drug dose selection, minimizing drug adverse reactions, increasing drug efficacy, and reducing the costive burdens.

Keyphrases

adverse drug
drug induced
emergency department
copy number
dna methylation
replacement therapy